Table 3.
Response to treatment for patients with pulmonary carcinoid.
| Regimen | Response rate |
Disease control rate |
Median PFS (months, range) |
|---|---|---|---|
| Etoposide + platinum (n = 13) | 23% | 69% | 7 (3–13) |
| Temozolomide-based (n = 14) | 14% | 57% | 10 (6–29) |
| Other cytotoxic chemotherapy (n = 11)a | 20% | 70% | 4 (3–18) |
| Any cytotoxic chemotherapy (n = 38) | 18% | 63% | 7 (3–29) |
| First-line cytotoxic chemotherapy (n = 20)b | 20% | 70% | 8 (3–18) |
| Second-line cytotoxic chemotherapy (n = 10) | 20% | 70% | 5 (3–10) |
| Third-line cytotoxic chemotherapy (n = 6) | 16% | 50% | 5 (4–12) |
| Octreotide-based (n = 20)c | 10% | 70% | 15 (6–72) |
a
11 regimens, 8 patients, including 1 patient treated with neoadjuvant cytotoxic chemotherapy.
b
Includes 4 patients treated with neoadjuvant cytotoxic chemotherapy.
c
20 regimens, 15 patients.